| Sex | p | |
---|---|---|---|
 | Males n (%) | Females n (%) | |
INH-Resistant (%) | 445(20.5) | 124(16.1) | 0.009 |
RFP-Resistant (%) | 345(15.9) | 92(12.0) | 0.009 |
MDR-TB (%) | 280(12.9) | 78(10.2) | 0.047 |
New patients | Â | Â | Â |
 INH-Resistant (%) | 396(20.3) | 90(14.5) | < 0.001 |
 RFP-Resistant (%) | 299(15.3) | 62(10.0) | < 0.001 |
 MDR-TB (%) | 243(12.4) | 51(8.2) | 0.004 |
Previously treated | Â | Â | Â |
 INH-Resistant (%) | 49(22.4) | 34(24.0) | 0.838 |
 RFP-Resistant (%) | 46(21.0) | 30(20.5) | 0.916 |
 MDR-TB (%) | 37(16.9) | 27(18.5) | 0.694 |
Smear+ (%) | Â | Â | Â |
 INH-Resistant (%) | 277(21.8) | 62(15.8) | 0.010 |
 RFP-Resistant (%) | 226(17.8) | 46(11.7) | 0.005 |
 MDR-TB (%) | 180(14.2) | 36(9.2) | 0.011 |
Smear- (%) | Â | Â | Â |
 INH-Resistant (%) | 139(18.5) | 54(17.2) | 0.619 |
 RFP-Resistant (%) | 94(12.5) | 38(12.1) | 0.875 |
 MDR-TB (%) | 78(10.4) | 35(11.1) | 0.708 |
Smear unknow (%) | Â | Â | Â |
 INH-Resistant (%) | 29(19.5) | 8(12.9) | 0.254 |
 RFP-Resistant (%) | 25(16.8) | 8(12.9) | 0.480 |
 MDR-TB (%) | 22(14.8) | 7(11.3) | 0.504 |
Urban | Â | Â | Â |
 INH-Resistant (%) | 197(24.8) | 53(18.7) | 0.036 |
 RFP-Resistant (%) | 162(20.4) | 42(14.8) | 0.039 |
 MDR-TB (%) | 134(16.9) | 33(11.6) | 0.036 |
Rural | Â | Â | Â |
 INH-Resistant (%) | 248(18.0) | 71(14.7) | 0.095 |
 RFP-Resistant (%) | 183(13.3) | 50(10.3) | 0.012 |
 MDR-TB (%) | 146(10.6) | 45(9.3) | 0.418 |
HRM-positive results of Test Year | Â | Â | Â |
 2019 | 651(24.6) | 215(21.1) | 0.027 |
 2020 | 679(16.5) | 237(12.8) | < 0.001 |
 2021 | 843(15.9) | 316(12.2) | < 0.001 |